Interestingly, specific CDK2 inhibition is found to be synthetically lethal to MYCN-driven neuroblastoma [22] suggesting a potential role for CDK2-inhibiting drugs also in MB-carrying amplifications in MYCN and perhaps also MYC. The gene discussed is MYC; the disease is neuroblastoma.